Belite Bio Files Regulatory Applications For Tinlarebant In Singapore, UK, Switzerland

Belite Bio (BLTE) will upgrade to the Nasdaq Global Select Market on October 19, 2026, maintaining its ticker. The company's lead drug, tinlarebant, showed positive Phase 3 results for Stargardt disease. BLTE stock is up 1.47% to $144.88.

Belite Bio (BLTE) announced its approval to move to Nasdaq's Global Select Market, starting Oct. 19. The company expects increased institutional investor attention and improved liquidity. Belite Bio is seeking approval for tinlarebant, its lead treatment for Stargardt disease, with the FDA setting a Feb. 12, 2027, action date.

Belite Bio (BLTE) has moved its securities listing to the Nasdaq Global Select Market, the highest tier, starting today. The company met the market's financial and liquidity standards. Belite Bio is a clinical-stage drug developer focusing on retinal diseases, with key trials ongoing for its lead candidate, tinlarebant.

H.C. Wainwright maintained a $245 price target for Belite Bio (BLTE) after regulatory submissions in three countries. The stock is up 88% over the past year, with analysts showing strong optimism. Belite Bio submitted applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company aims for a global launch, with a first-mover advantage if approved.

Belite Bio (BLTE) submitted Marketing Authorization Applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company also filed applications in the US and Japan, with the US application receiving Priority Review. Tinlarebant met its primary endpoint in a Phase 3 trial and has received several regulatory designations.

Belite Bio (BLTE) filed Marketing Authorization Applications for tinlarebant in the UK, Switzerland, and Singapore to treat Stargardt Disease Type 1. If approved, it would be the first treatment for this condition in these markets. The company also has applications pending in the U.S. and Japan, with a U.S. target action date of February 12, 2027. Success could open new markets and generate revenue.